Nasdaq cprx.

Aug 27, 2022 · Anyone interested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) should probably be aware that the Chief Commercial Officer, Jeffrey Del Carmen, recently divested US$199k worth of shares in the ... Based on analysts offering 12 month price targets for CPRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with..Catalyst Pharmaceuticals, Inc. (CPRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Catalyst Pharmaceuticals, ...

Find the latest on option chains for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Their CPRX share price targets range from $24.00 to $27.00. On average, they expect the company's share price to reach $24.75 in the next twelve months. This …

Jul 3, 2023 · Catalyst Pharmaceuticals had non-GAAP profits of 41 cents, a full dime a share over the consensus. On a GAAP basis, earnings were 26 cents a share for the quarter, an improvement of 117% from ... CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the …

Selling, general and administrative expenses totaled $14.7 million, up from $13.2 million reported in the year-ago quarter. As of Dec 31, 2022, CPRX had cash, cash equivalents and investments ...Catalyst Pharmaceuticals (NASDAQ:CPRX) is another biotech that has performed strongly over the past twelve months. During this timeframe, shares have nearly doubled in price. During this timeframe ...Dec 1, 2023 · See the latest Catalyst Pharmaceuticals Inc stock price (CPRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Catalyst also expects a cash balance of $191 million as of 2021-end, without any funded debt. For 2022, the company expects total revenues for 2022 in the range of $195-$205 million, suggesting a ...

Catalyst also expects a cash balance of $191 million as of 2021-end, without any funded debt. For 2022, the company expects total revenues for 2022 in the range of $195-$205 million, suggesting a ...

Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Target Price at $24.75 americanbankingnews.com - November 13 at 1:28 AM: Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 5% americanbankingnews.com - November 12 at 4:00 AM: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2023 Earnings …

Feb 28, 2023 · Catalyst Pharmaceuticals (NASDAQ:CPRX) is another biotech that has performed strongly over the past twelve months. During this timeframe, shares have nearly doubled in price. During this timeframe ... CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ETCompany Participants. Patrick McEnany - Chairman, Chief Executive Officer. Alicia Grande - Vice ...Fintel reports that on August 11, 2023, Cantor Fitzgerald maintained coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 52.12% UpsideCatalyst Pharmaceuticals, Inc. Common Stock (CPRX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...

Did Catalyst Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Catalyst Pharmaceuticals (NASDAQ: ...Jul 30, 2021 · You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart. NasdaqCM:CPRX Earnings and Revenue History July 30th 2021 The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Fiscal Q3 2023 ended 9/30/23. Reported on 11/8/23. Get the latest Catalyst Pharmaceuticals Inc (CPRX) real-time quote, historical performance, charts, and other financial information to help you...Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago.

(NASDAQ:CPRX), announced on June 20, 2023 [1]. The proceeds from the agreement extend Santhera's cash reach into 2025. Together with the expected income ...Past criteria checks 1/6. Catalyst Pharmaceuticals has been growing earnings at an average annual rate of 41.7%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 40.6% per year. Catalyst Pharmaceuticals's return on equity is 17.8%, and it has net margins of 17.8%.

CPRX: NASDAQ (Stock) CATALYST PHARMACEUTICALS, INC. DEC 01, 11:00 AM EST $14.82 +0% Dividend (Fwd) $0.00 Yield (Fwd) Annualized forward dividend yield. Multiplies the ...Catalyst Pharmaceuticals’ (NASDAQ:CPRX) top drug is Firdapse, which is used to treat adults with Lambert-Eaton Myasthenic Syndrome, a rare condition that affects signals sent from nerves to ...Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.16 per share a year ago.Deerfield Management was the largest stakeholder in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the third quarter, holding 4.9 million shares worth $62.8 million. In total, 18 funds were long ...Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high ...CPRX closed Monday's trading at $4.26, up 5.31%. In after-hours, the stock was down 16.06% at $3.58. ... views and opinions expressed herein are the views and opinions of the author and do not ...Catalyst Pharmaceuticals (NASDAQ:CPRX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior business?We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, …

CORAL GABLES, Fla. , Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany , Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime. Oct 13, 2023.

Aug 5, 2023 · This value model looks for companies with high return on capital and earnings yields. CATALYST PHARMACEUTICALS INC ( CPRX) is a small-cap growth stock in the Biotechnology & Drugs industry. The ...

Catalyst also expects a cash balance of $191 million as of 2021-end, without any funded debt. For 2022, the company expects total revenues for 2022 in the range of $195-$205 million, suggesting a ...The latest price target for . Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by Cantor Fitzgerald on August 22, 2023.The analyst firm set a price target for $27.00 expecting CPRX to rise to ...Sep 21, 2022 · The average CPRX stock price target of $16.70 per share implies 34% upside over the next twelve months. A strong rally in Catalyst Pharmaceuticals stock might have been amplified by institutional ... Catalyst Pharmaceuticals' CEO is Pat McEnany, appointed in Jan 2002, has a tenure of 21.83 years. total yearly compensation is $6.92M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 3.86% of the company’s shares, worth $57.92M. The average tenure of the management team and the board of …Nov 30, 2023 · NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, News & Analysis Should You Buy or Sell Catalyst Pharmaceuticals Stock? Get The Latest CPRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Should You Buy or Sell Catalyst Pharmaceuticals Stock? Cetera Investment Advisers grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,223 shares of the biopharmaceutical company’s stock after acquiring an additional 1,096 shares during the quarter. Cetera […]This value model looks for companies with high return on capital and earnings yields. CATALYST PHARMACEUTICALS INC ( CPRX) is a small-cap growth stock in the Biotechnology & Drugs industry. The ...Then look at the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price. It's 715% higher th Shareholders Are Raving About How The Catalyst Pharmaceuticals (NASDAQ:CPRX) Share Price Increased ...Catalyst Pharmaceuticals Inc stock price (CPRX) NASDAQ: CPRX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Catalyst Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.CORAL GABLES, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has successfully completed …Catalyst Pharmaceuticals' CEO is Pat McEnany, appointed in Jan 2002, has a tenure of 21.83 years. total yearly compensation is $6.92M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 3.86% of the company’s shares, worth $57.92M. The average tenure of the management team and the board of …

Catalyst Pharmaceuticals CPRX has reached a settlement with Jacobus Pharmaceutical Company, Inc. and PANTHERx Rare LLC, with regard to the ongoing patent infringement litigation over its sole ...Mar 31, 2020 · Find the latest Revenue & EPS data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. Back to CPRX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Instagram:https://instagram. retail execution software marketgreenbiz financialfinancial advisors in pittsburghmedia training online Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.16 per share a year ago.Catalyst Pharmaceuticals, Inc. CPRX announced that it will invest heavily in Research and Development (R&D), including acquiring earlier-stage opportunities, and expand its product portfolio ... dell stock codeself employed dental coverage Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Nov 30, 2023 · The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has plunged by -1.13 when compared to previous closing price of 14.21, but the company has seen a 2.26% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-09 that Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales […] mortgage lender in texas Selling, general and administrative expenses totaled $14.7 million, up from $13.2 million reported in the year-ago quarter. As of Dec 31, 2022, CPRX had cash, cash equivalents and investments ...Nov 14, 2022 · While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 92.3% this year, crushing the industry ...